CD8A and neoplasm: CAFs can suppress immune cell activity in the TME in multiple ways including the production of immunosuppressive cytokines and immune checkpoint ligands, anti-tumor CD8+ T-cells exclusion, and by modulating the functional differentiation of tumor-infiltrating inflammatory cells [68,69].